Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HARMONY BIOSCIENCES HOLDINGS, INC.

(HRMY)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
42.47 USD   -0.93%
08/23INSIDER SELL : Harmony Biosciences Holdings
MT
08/17Harmony biosciences to participate in upcoming investor conferences
PR
08/16INSIDER SELL : Harmony Biosciences Holdings
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/19/2022 09/20/2022 09/21/2022 09/22/2022 09/23/2022 Date
43.55(c) 43.43(c) 42.78(c) 42.87(c) 42.47(c) Last
376 378 380 600 342 851 366 883 388 385 Volume
-0.66% -0.28% -1.50% +0.21% -0.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 430 M - -
Net income 2022 83,5 M - -
Net cash position 2022 148 M - -
P/E ratio 2022 30,8x
Yield 2022 -
Sales 2023 590 M - -
Net income 2023 172 M - -
Net cash position 2023 414 M - -
P/E ratio 2023 15,2x
Yield 2023 -
Capitalization 2 513 M 2 513 M -
EV / Sales 2022 5,50x
EV / Sales 2023 3,56x
Nbr of Employees 180
Free-Float 80,1%
More Financials
Company
Harmony Biosciences Holdings, Inc. is a holding company. The Company’s operations are conducted through its wholly owned subsidiary, Harmony Biosciences, LLC (Harmony). The Company is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with neurological disorders. The Company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action (MOA)... 
Sector
Pharmaceuticals
Calendar
11/17Earnings Release
More about the company
Ratings of Harmony Biosciences Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about HARMONY BIOSCIENCES HOLDINGS, INC.
08/23INSIDER SELL : Harmony Biosciences Holdings
MT
08/17Harmony biosciences to participate in upcoming investor conferences
PR
08/16INSIDER SELL : Harmony Biosciences Holdings
MT
08/11INSIDER SELL : Harmony Biosciences Holdings
MT
08/11Reuters-schedule/…
RE
08/10Reuters-schedule/…
RE
08/09INSIDER SELL : Harmony Biosciences Holdings
MT
08/04Goldman Sachs Raises Price Target on Harmony Biosciences to $58 From $56, Maintains Neu..
MT
08/04Mizuho Securities Adjusts Price Target on Harmony Biosciences Holdings to $60 From $64,..
MT
08/03INSIDER SELL : Harmony Biosciences Holdings
MT
08/03Oppenheimer Adjusts Harmony Biosciences Holdings Price Target to $67 From $62, Maintain..
MT
08/03Raymond James Adjusts Price Target on Harmony Biosciences Holdings to $60 From $58, Kee..
MT
08/03Jefferies Downgrades Harmony Biosciences Holdings to Hold From Buy; Price Target is $57
MT
08/02Harmony Biosciences Holdings Reports Higher Q2 Earnings, Revenue
MT
08/02TRANSCRIPT : Harmony Biosciences Holdings, Inc., Q2 2022 Earnings Call, Aug 02, 2022
CI
More news
News in other languages on HARMONY BIOSCIENCES HOLDINGS, INC.
08/11VENTE D'INITIÉS : Harmony Biosciences Holdings
08/02Harmony Biosciences Holdings annonce une hausse de ses bénéfices et de ses revenus au d..
08/02Harmony Biosciences Holdings, Inc. annonce ses résultats pour le deuxième trimestre et ..
07/21VENTE D'INITIÉS : Harmony Biosciences Holdings
07/08VENTE PAR UN INITIÉ : Harmony Biosciences Holdings
More news
Analyst Recommendations on HARMONY BIOSCIENCES HOLDINGS, INC.
More recommendations
ETFs positioned on HARMONY BIOSCIENCES HOLDINGS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
SPDR S&P Pharmaceuticals ETF - USD3.52%-5.80%United_States
First Trust US Equity Opportunities - USD0.35%-7.02%United_States
IShares Nasdaq US Biotechnology - USD0.31%-6.06%United_States
IShares Nasdaq US Biotechnology (D) - USD0.31%-5.67%United_States
SPDR S&P 600 Small Cap Growth ETF - USD0.16%-4.62%United_States
More ETFs positioned on HARMONY BIOSCIENCES HOLDINGS, INC.
Chart HARMONY BIOSCIENCES HOLDINGS, INC.
Duration : Period :
Harmony Biosciences Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HARMONY BIOSCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 42,47 $
Average target price 61,50 $
Spread / Average Target 44,8%
EPS Revisions
Managers and Directors
John C.s Jacobs President, Chief Executive Officer & Director
Sandipkumar S. Kapadia Chief Financial Officer
Jeffrey S. Aronin Non-Executive Chairman
Jeffrey M. Dayno Chief Medical Officer
David Bradshaw Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
HARMONY BIOSCIENCES HOLDINGS, INC.-0.40%2 513
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392